CEL-SCI Corporation Stock News

One of your neighbors posted in Neighbor News. Click through to read what they have to say. (The views expressed in this post are the author’s own.)

CEL-SCI’s Pivotal Phase 3 Study has reached the required number of events to evaluate data for Multikine in treatment of Head and Neck Cancer.

CEL-SCI’s Pivotal Phase 3 Study has reached the required number of events to evaluate data for Multikine in treatment of Head and Neck Cancer.

The developing country of more than 95 million people has less than 300 cases and no deaths

Gainers Mesoblast Limited (NASDAQ: MESO) shares climbed 139.5% to close at $15.45 on Friday after the company reported 10 out of 12 patients with ventilator-dependent...

Who has the upper ground in a war between investors and short-sellers about whether a biotech's clinical trial for treating head and neck cancer can succeed?

CEL-SCI reports recent data review by the Independent Data Monitoring Committee for its pivotal Phase 3 head and neck cancer study.

It’s natural during a crisis… Investors want to find the companies that will help solve the problem and come out as big winners. The company or companies that do produce effective treatments and v

Brazil's central bank spent 1.3 million Brazilian reals (USD $250K) over two years building its new database for financial regulators on Quorum, replacing a slow and expensive paper-based system with

Important update for CEL-SCI Corporation Annual Meeting of Shareholders.